% | $
Quotes you view appear here for quick access.

Sarepta Therapeutics, Inc. Message Board

  • dinepat203 dinepat203 Apr 25, 2014 9:50 AM Flag

    will SRPTfind new patients? Now there are many options better than SRPT.

    This Board is well educated to understand that.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • 11111111111111111........................
      There are currently no marketed therapies approved to treat the underlying cause of nmDMD or nmCF. The European Medicines Agency, or EMA, has designated ataluren as an orphan medicinal product and the U.S. Food and Drug Administration, or FDA, has granted orphan drug designation to ataluren for the treatment of both nmDMD and nmCF.

      At PTC, currently have ongoing collaborations with Roche and the SMA Foundation for the development and commercialization of compounds for the treatment of spinal muscular atrophy

      Liestal, Switzerland, April 16, 2013 - Santhera Pharmaceuticals (SIX: SANN) announced today that the Phase III DELOS study of orally administered Catena® in patients with Duchenne Muscular Dystrophy (DMD) successfully passed a planned futility and safety analysis. The independent Data Safety Monitoring Board (DSMB) for DELOS informed Santhera that the study has a reasonable chance of achieving its primary endpoint for improving or delaying the loss of respiratory function in Duchenne patients not using corticosteroids and since no safety issues were detected, recommended that the study should continue as planned.

16.8604-1.1596(-6.44%)10:52 AMEDT